Roche acquires IQuum to strengthen offerings in molecular diagnostics
7 April 2014 | By Roche
IQuum’s unique products will allow Roche to quickly enter the point of care segment of molecular diagnostics...
List view / Grid view
News
Pfizer’s novel CDK 4/6 inhibitor palbociclib plus letrozole significantly prolonged progression-free survival in patients with advanced breast cancer
7 April 2014 | By Pfizer
Final Phase 2 PALOMA-1 data to be presented for potential first-in-class palbociclib...
Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
7 April 2014 | By Novartis
Novartis announced that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign...
Amgen provides update on Phase 3 study of talimogene laherparepvec in patients with metastatic melanoma
7 April 2014 | By Amgen
Amgen announced top-line results from the primary overall survival analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec...
Daiichi Sankyo agrees to vote its shares in Ranbaxy in favor of Sun Pharma’s Acquisition
7 April 2014 | By Daiichi Sankyo
Pursuant to the merger transaction announced between Ranbaxy Laboratories Limited and Sun Pharmaceutical Industries Ltd. announces that it has agreed to vote its shares in Ranbaxy in favor of Sun Pharma’s acquisition of 100%...
Treatment with once-monthly Abilify Maintena® (aripiprazole) significantly reduces hospitalisation rates for patients with schizophrenia compared with daily oral antipsychotics
7 April 2014 | By Lundbeck
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Europe Ltd. (Otsuka) announced results from the final analysis of a mirror-image study showing statistically significant reductions (p
Subpoena for Ranbaxy’s Toansa Plant
7 April 2014 | By Daiichi Sankyo
Attached is the statement of Ranbaxy Laboratories, a subsidiary of Daiichi Sankyo Company, Limited, which was issued on April 7th, 2014...
Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways
4 April 2014 | By Novartis
Novartis announced that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research...
Merck receives 2014 ENERGY STAR Sustained Excellence Award from U.S. Environmental Protection Agency
4 April 2014 | By Merck
Merck announced that it has received an ENERGY STAR 2014 Partner of the Year – Sustained Excellence Award from the U.S...
Daiichi Sankyo and UC San Francisco announce collaboration in drug discovery research for neurodegenerative diseases
3 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Co., Ltd. and University of California, San Francisco announced that they have established a drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases...
Penn Pharma Enter into manufacturing agreement with BioAlliance
3 April 2014 | By Penn Pharma
Pharmaceutical manufacturer Penn Pharma has announced an agreement with BioAlliance Pharma to manufacture one of their leading development products in Penn’s new contained manufacturing facility...
New general concept for the treatment of cancer
3 April 2014 | By Karolinska Institutet
A team of researchers from five Swedish universities, led by Karolinska Institutet and the Science for Life Laboratory, have identified a new way of treating cancer...
Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer
2 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer (NSCLC) patients...
Results from Phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology
2 April 2014 | By GlaxoSmithKline
Data from the first patient preference study in advanced renal cell carcinoma are published in the Journal of Clinical Oncology...
Daiichi Sankyo initiates phase 3 ENSURE-AF study, investigating once-daily edoxaban in patients with atrial fibrillation undergoing cardioversion
1 April 2014 | By Daiichi Sankyo Company
First patient enrolled in largest planned phase 3 study evaluating a novel oral antico-agulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion...
